Most importantly, SGLT-2 inhibitors were found to be significantly better in reducing cardiovascular and all-cause mortality regardless of existing cardiovascular disease or CKD in patients with T2DM. This evidence concerns the gene SLC5A2 and cardiovascular disorder.